Huang Binjie, Zhu Miaomiao, Wu Yali, Qin Qiyuan, He Yanjiong, Zhou Zuolin, Huang Xiaoyan, Wang Hui, Ma Tenghui
Objective To explore the occurrences and risk factors of low anterior resection syndrome (LARS) in low rectal cancer patients with neoadjuvant chemotherapy followed by curative restorative anterior resection. Methods For this cross-sectional study, 129 low rectal cancer patients on neoadjuvant chemotherapy were recruited at Sixth Affiliated Hospital between September, 2010 and December, 2020. Those with curative restorative anterior resection were included while those with pelvic radiation, stoma without closure and local tumor recurrence or metastasis excluded. LARS score was utilized for assessing bowel function at least 1 year post-restoration. They were categorized into three groups of no LARS (0-20 points), mild LARS (21-29 points) and severe LARS (30-42 points). Baseline profiles, tumor features, treatment strategies and postoperative complications were included into Logistic regression analysis for assessing the risk factors for overall and severe LARS. Results 30 patients became lost to follow-ups. Only in preoperative body mass index (23.0±3.0 vs. 20.8±2.9) and pathological T stage (pT0-2: 62.8% vs 26.7%)(P<0.05),differed significantly between the follow-up and lost-follow-up group. There were 84 males and 45 females with an average age of (56.4±12.4) year and an average tumor diameter of (3.8±0.7) cm. Preoperative chemotherapeutic regimen CapeOX/FOLFOX (78.3%) or FOLFOXIRI was offered. 29.5%(38/129) underwent transanal and transabdominal laparoscopy, 71.4%(92/129) had intersphincteric resection, 74.4%(96/129) received prophylactic stomas and 13.2%(17/129) developed postoperative anastomotic leakage. During a median follow-up period of 3.9(1.0-10.4) year, there were an overall LARS incidence of 55.0%(71/129) and a severe LARS incidence of 24.0%(31/129). Constipation (defecation less than once daily) and frequent defecation within 1h were the most common symptoms. Logistic univariate regression analysis indicated that male gender (OR=2.565, P=0.012), anastomotic leakage (OR=4.503, P=0.015) and bowel continuity restoration time ≤4 year (OR=2.285, P=0.021) were risk factors for overall LARS; male gender (OR=2.754, P=0.037), anastomotic leakage (OR=6.190, P=0.001), intersphincteric resection (OR=3.427, P=0.026) and hand-sewn anastomosis (OR=3.538, P=0.008) were risk factors for severe LARS. Multivariate Logistic regression analysis revealed that male gender (OR=2.885, P=0.013), postoperative anastomotic leakage (OR=3.866, P=0.046) and bowel continuity restoration time ≤4 year (OR=2.871, P=0.009) were independent risk factors for overall LARS. However, only anastomotic leakage (OR=5.155, P=0.004) was an independent risk factor for severe LARS. Conclusion Nearly half of low rectal cancer patients on neoadjuvant chemotherapy develop LARS after restorative surgery. Constipation (defecation less than once daily) and frequent defecation within 1h are the most common symptoms. LARS symptoms may self-alleviate overtime. Patients of anastomotic leakage tend to have a worse defecation prognosis.